Shereen Abdelghaffar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shereen Abdelghaffar has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Amin Roshdy Soliman
Cairo University, Egypt
3 shared publications - Inass Shaltout
Internal Medicine and Diabetes Department, Faculty of Medicine, Cairo University, Cairo, Egypt
3 shared publications - Mona A. Hegazy
Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt
3 shared publications - Amr Abdel Hady El Meligi
Internal Medicine and Endocrinology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications Dina Soliman
Department of Anesthesiology, SICU and Pain, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt
2 shared publications- Rabab Mahmoud Ahmed
Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-31
Management of Obesity in Special Populations and Limited-Resource Settings: An Egyptian Medical Position Statement
Background: Obesity/adiposity-based chronic disease is a chronic progressive relapsing disease linked to several comorbidities, with rising prevalence in Egypt. Limited local guidelines and healthcare challenges necessitate evidence-based, culturally adapted strategies. Methods: The Egyptian Medical Association for the Study of Obesity convened a clinical multidisciplinary panel to develop consensus recommendations. Evidence was synthesized from literature, prioritizing resource-limited settings and special situations. Result: Assessment: Move beyond Body Mass Index to include waist circumference, waist/height ratio, body composition, and screening for obesity-related complications and diseases. Lifestyle Interventions: a-Nutrition: Mediterranean/dietary approach to stop hypertension diets, slow eating, and supervised fasting (eg Ramadan and Christian). b-Activity: Culturally tailored approaches (eg prayer-time movement and Arabic apps). c-Behavior: Cognitive-behavioral therapy and family-inclusive support. Pharmacotherapy: Use of approved agents (orlistat, naltrexone/bupropion, liraglutide, semaglutide, and tirzepatide) according to obesity-related complications and diseases and age group. Avoid GLP-1, GLP-1/GIP analogues in patients with medullary thyroid cancer, and all agents during pregnancy. Bariatric Surgery: Indicated for body mass index ≥ 40 kg/m2 (or ≥ 35 with obesity-related complications and diseases), with lifelong micronutrient supplementation. Special Populations: a-Adolescents: Focus on growth, not only weight-loss; consider pharmacotherapy in different age groups. b-Elderly: Prioritize muscle preservation; avoid weight loss unless obesity-related complications and diseases exist. c-Pregnancy: No weight loss; delay postpartum interventions until lactation is established. Policy Actions: Mandate food labeling, tax sugar-sweetened beverages, and integrate obesity services into primary healthcare. Conclusion: These recommendations provide a pragmatic framework for obesity/adiposity-based chronic disease management in Egypt, emphasizing affordable, patient-centered care, and clinical multidisciplinary collaboration and policy support.
- 1 October 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-31
Open AccessManagement of Obesity in Special Populations and Limited-Resource Settings: An Egyptian Medical Position Statement
Background: Obesity/adiposity-based chronic disease is a chronic progressive relapsing disease linked to several comorbidities, with rising prevalence in Egypt. Limited local guidelines and healthcare challenges necessitate evidence-based, culturally adapted strategies. Methods: The Egyptian Medical Association for the Study of Obesity convened a clinical multidisciplinary panel to develop consensus recommendations. Evidence was synthesized from literature, prioritizing resource-limited settings and special situations. Result: Assessment: Move beyond Body Mass Index to include waist circumference, waist/height ratio, body composition, and screening for obesity-related complications and diseases. Lifestyle Interventions: a-Nutrition: Mediterranean/dietary approach to stop hypertension diets, slow eating, and supervised fasting (eg Ramadan and Christian). b-Activity: Culturally tailored approaches (eg prayer-time movement and Arabic apps). c-Behavior: Cognitive-behavioral therapy and family-inclusive support. Pharmacotherapy: Use of approved agents (orlistat, naltrexone/bupropion, liraglutide, semaglutide, and tirzepatide) according to obesity-related complications and diseases and age group. Avoid GLP-1, GLP-1/GIP analogues in patients with medullary thyroid cancer, and all agents during pregnancy. Bariatric Surgery: Indicated for body mass index ≥ 40 kg/m2 (or ≥ 35 with obesity-related complications and diseases), with lifelong micronutrient supplementation. Special Populations: a-Adolescents: Focus on growth, not only weight-loss; consider pharmacotherapy in different age groups. b-Elderly: Prioritize muscle preservation; avoid weight loss unless obesity-related complications and diseases exist. c-Pregnancy: No weight loss; delay postpartum interventions until lactation is established. Policy Actions: Mandate food labeling, tax sugar-sweetened beverages, and integrate obesity services into primary healthcare. Conclusion: These recommendations provide a pragmatic framework for obesity/adiposity-based chronic disease management in Egypt, emphasizing affordable, patient-centered care, and clinical multidisciplinary collaboration and policy support.
- Open Access
- 6 October 2025
- Published by Springer Nature in Cardiovascular Diabetology – Endocrinology Reports
- Vol. 11 (1) , 1-18
Non-diabetic hypoglycemia: bridging gaps in diagnosis and treatment: a position statement report by the Arabic Association for the Study of Diabetes and Metabolism (AASD)
Background: Non-diabetic hypoglycemia presents a substantial diagnostic challenge due to its diverse and often nonspecific symptomatology. The resultant delay in diagnosis can lead to a myriad of misdiagnoses. This misidentification not only prolongs patient suffering but also elevates the risk of severe complications, such as permanent neurologic damage and mortality. Recognizing the clinical nuances of non-diabetic hypoglycemia is paramount for timely and accurate diagnosis, which ultimately enhances patient outcomes and safety. Main Body: A position statement has been formulated by the Arabic Association for the Study of Diabetes and Metabolism (AASD) to address the complexities of diagnosing non-diabetic hypoglycemia. This statement highlights the challenges and pitfalls, covering key areas such as the vast spectrum of non-diabetic hypoglycemia within underreported subspecialties. It aims to elucidate the critical need for heightened clinical awareness and multidisciplinary management approaches to mitigate the profound impacts on patient health. Additionally, the statement provides guidance for overcoming barriers to optimal care. The team has distilled their experience into clinical algorithms to simplify information for healthcare professionals. Conclusion: Non-diabetic hypoglycemia is a rare condition that requires a comprehensive approach, including detailed history, medication review, and physical examination. Common pitfalls in diagnosis and management should be understood to avoid unnecessary evaluation and costs while avoiding misdiagnosis of patients with treatable or serious disorders.
- 6 October 2025
- Published by Springer Nature in Cardiovascular Diabetology – Endocrinology Reports
- Vol. 11 (1) , 1-18
Open AccessNon-diabetic hypoglycemia: bridging gaps in diagnosis and treatment: a position statement report by the Arabic Association for the Study of Diabetes and Metabolism (AASD)
Background: Non-diabetic hypoglycemia presents a substantial diagnostic challenge due to its diverse and often nonspecific symptomatology. The resultant delay in diagnosis can lead to a myriad of misdiagnoses. This misidentification not only prolongs patient suffering but also elevates the risk of severe complications, such as permanent neurologic damage and mortality. Recognizing the clinical nuances of non-diabetic hypoglycemia is paramount for timely and accurate diagnosis, which ultimately enhances patient outcomes and safety. Main Body: A position statement has been formulated by the Arabic Association for the Study of Diabetes and Metabolism (AASD) to address the complexities of diagnosing non-diabetic hypoglycemia. This statement highlights the challenges and pitfalls, covering key areas such as the vast spectrum of non-diabetic hypoglycemia within underreported subspecialties. It aims to elucidate the critical need for heightened clinical awareness and multidisciplinary management approaches to mitigate the profound impacts on patient health. Additionally, the statement provides guidance for overcoming barriers to optimal care. The team has distilled their experience into clinical algorithms to simplify information for healthcare professionals. Conclusion: Non-diabetic hypoglycemia is a rare condition that requires a comprehensive approach, including detailed history, medication review, and physical examination. Common pitfalls in diagnosis and management should be understood to avoid unnecessary evaluation and costs while avoiding misdiagnosis of patients with treatable or serious disorders.
- Open Access
- 3 September 2024
- Published by Springer Nature in Journal of Health, Population and Nutrition
- Vol. 43 (1) , 1-14
Dietary recommendations for people with diabetes in special situations: a position statement report by Arabic Association for the Study of Diabetes and metabolism (AASD)
Background: Diabetes is a significant global health concern. Regional factors play a crucial role in determining the appropriate diet for patients. Main body: The Arabic Association for the Study of Diabetes and Metabolism has developed a position statement that addresses the dietary needs of patients in the context of low income and cultural dietary habits. This statement aims to explore the most suitable diet for Middle East and North Africa (MENA) region and provide guidance for physicians to overcome barriers in optimal care. While most dietary guidelines focus on uncomplicated diabetes, it’s essential to recognize that diabetes often coexists with other common diseases in our region. Conclusion: International guidelines cannot be directly applied to the Egypt and Arab countries due to cultural and dietary differences. Our position statement shares valuable insights into managing diabetes in special situations and diverse clinical settings within this region. These recommendations are flexible, considering personal, cultural, and traditional differences.
- 3 September 2024
- Published by Springer Nature in Journal of Health, Population and Nutrition
- Vol. 43 (1) , 1-14
Open AccessDietary recommendations for people with diabetes in special situations: a position statement report by Arabic Association for the Study of Diabetes and metabolism (AASD)
Background: Diabetes is a significant global health concern. Regional factors play a crucial role in determining the appropriate diet for patients. Main body: The Arabic Association for the Study of Diabetes and Metabolism has developed a position statement that addresses the dietary needs of patients in the context of low income and cultural dietary habits. This statement aims to explore the most suitable diet for Middle East and North Africa (MENA) region and provide guidance for physicians to overcome barriers in optimal care. While most dietary guidelines focus on uncomplicated diabetes, it’s essential to recognize that diabetes often coexists with other common diseases in our region. Conclusion: International guidelines cannot be directly applied to the Egypt and Arab countries due to cultural and dietary differences. Our position statement shares valuable insights into managing diabetes in special situations and diverse clinical settings within this region. These recommendations are flexible, considering personal, cultural, and traditional differences.
- Open Access
- 1 September 2024
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 20 (7) , 1-22
Risk Stratification in People with Diabetes for Fasting During Ramadan: Consensus from Arabic Association for the Study of Diabetes and Metabolism
Background: Current international guidelines recommend a pre-Ramadan risk assessment for people with diabetes (PwDM) who plan on fasting during the Holy month. However, a comprehensive risk assessment-based recommendation for the management of PwDM intending to fast is still controversial. Therefore, the Arabic Association for the Study of Diabetes and Metabolism (AASD) developed this consensus to provide further insights into risk stratification in PwDM intending to fast during Ramadan. Methods: The present consensus was based on the three-step modified Delphi method. The modified Delphi method is based on a series of voting rounds and in-between meetings of the expert panel to reach agreements on the statements that did not reach the consensus level during voting. The panel group comprised professors and consultants in endocrinology (both adult and pediatric). Other members included experts in the fields of cardiovascular medicine, nephrology, ophthalmology, and vascular surgery, affiliated with academic institutions in Egypt. Result: In PwDM who intend to fast during Ramadan, risk stratification is crucial to optimize patient outcomes and prevent serious complications. The present consensus provides risk assessment of those living with diabetes according to several factors, including the type of diabetes, presence, and severity of complications, number of fasting hours, and other socioeconomic factors. According to their risk factors, patients were classified into four categories (very high, high, moderate, and low risk). Conclusion: Future research is warranted due to the controversial literature regarding the impact of fasting on certain comorbidities.
- 1 September 2024
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 20 (7) , 1-22
Open AccessRisk Stratification in People with Diabetes for Fasting During Ramadan: Consensus from Arabic Association for the Study of Diabetes and Metabolism
Background: Current international guidelines recommend a pre-Ramadan risk assessment for people with diabetes (PwDM) who plan on fasting during the Holy month. However, a comprehensive risk assessment-based recommendation for the management of PwDM intending to fast is still controversial. Therefore, the Arabic Association for the Study of Diabetes and Metabolism (AASD) developed this consensus to provide further insights into risk stratification in PwDM intending to fast during Ramadan. Methods: The present consensus was based on the three-step modified Delphi method. The modified Delphi method is based on a series of voting rounds and in-between meetings of the expert panel to reach agreements on the statements that did not reach the consensus level during voting. The panel group comprised professors and consultants in endocrinology (both adult and pediatric). Other members included experts in the fields of cardiovascular medicine, nephrology, ophthalmology, and vascular surgery, affiliated with academic institutions in Egypt. Result: In PwDM who intend to fast during Ramadan, risk stratification is crucial to optimize patient outcomes and prevent serious complications. The present consensus provides risk assessment of those living with diabetes according to several factors, including the type of diabetes, presence, and severity of complications, number of fasting hours, and other socioeconomic factors. According to their risk factors, patients were classified into four categories (very high, high, moderate, and low risk). Conclusion: Future research is warranted due to the controversial literature regarding the impact of fasting on certain comorbidities.
- Open Access
- 1 July 2020
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 13, 2485-2494
MicroRNAs and Risk Factors for Diabetic Nephropathy in Egyptian Children and Adolescents with Type 1 Diabetes
Purpose: Currently available markers for early detection of diabetic nephropathy (DN), the leading cause of end stage renal disease, have some limitations. There is insufficient evidence from previous studies about the role of several circulating microRNAs (miRNAs) in the early development of DN. This study aimed to describe the expression of miRNA-377, miRNA-93, miRNA-25, miRNA-216a, and miRNA-21 in a sample of type 1 diabetic children and adolescents to explore their association with DN and some indices of kidney injury. Patients and Methods: Seventy type 1 diabetic patients, with 5 years’ duration of diabetes or more, were recruited from Children’s Hospital, Faculty of Medicine, Cairo University. Quantitative real-time reverse-transcription PCR (qRT-PCR) was used to measure the expression of the above mentioned miRNAs in serum and to assess its association with DN, and the studied risk factors. Results: There was a significantly higher percentage of up-regulation of miRNA-377 and miRNA-93 (P=0.03, 0.02, respectively) in addition to significant down-regulation of miRNA-25 (P=0.01) in patients with DN than in patients without DN. In patients with DN, expression of miR-216a was significantly negatively correlated with creatinine (r=− 0.4, P=0.04) and positively correlated with eGFR using creatinine (r=0.5, P=0.03). In the same group, expression of miR-21 was positively correlated with urinary cystatin C (r=0.6, P=0.01) and was negatively correlated with e-GFR using cystatin c (r=− 0.6, P=0.01). miRNA-93 was associated with increased risk (odds ratio=15, 95% CI=12.03– 24.63, P=0.01), while miRNA-25 was associated with decreased risk for albuminuria (odds ratio=0.15, 95% CI=0.08– 0.55, P=0.03). Conclusion: miRNA-377, miRNA-93, miRNA-216a, and miRNA-21 may be implicated in the pathogenesis of DN, while miRNA-25 may have a reno-protective role. More studies are needed to document the value of these miRNAs as diagnostic biomarkers as well as therapeutic targets in DN.
- 1 July 2020
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 13, 2485-2494
Open AccessMicroRNAs and Risk Factors for Diabetic Nephropathy in Egyptian Children and Adolescents with Type 1 Diabetes
Purpose: Currently available markers for early detection of diabetic nephropathy (DN), the leading cause of end stage renal disease, have some limitations. There is insufficient evidence from previous studies about the role of several circulating microRNAs (miRNAs) in the early development of DN. This study aimed to describe the expression of miRNA-377, miRNA-93, miRNA-25, miRNA-216a, and miRNA-21 in a sample of type 1 diabetic children and adolescents to explore their association with DN and some indices of kidney injury. Patients and Methods: Seventy type 1 diabetic patients, with 5 years’ duration of diabetes or more, were recruited from Children’s Hospital, Faculty of Medicine, Cairo University. Quantitative real-time reverse-transcription PCR (qRT-PCR) was used to measure the expression of the above mentioned miRNAs in serum and to assess its association with DN, and the studied risk factors. Results: There was a significantly higher percentage of up-regulation of miRNA-377 and miRNA-93 (P=0.03, 0.02, respectively) in addition to significant down-regulation of miRNA-25 (P=0.01) in patients with DN than in patients without DN. In patients with DN, expression of miR-216a was significantly negatively correlated with creatinine (r=− 0.4, P=0.04) and positively correlated with eGFR using creatinine (r=0.5, P=0.03). In the same group, expression of miR-21 was positively correlated with urinary cystatin C (r=0.6, P=0.01) and was negatively correlated with e-GFR using cystatin c (r=− 0.6, P=0.01). miRNA-93 was associated with increased risk (odds ratio=15, 95% CI=12.03– 24.63, P=0.01), while miRNA-25 was associated with decreased risk for albuminuria (odds ratio=0.15, 95% CI=0.08– 0.55, P=0.03). Conclusion: miRNA-377, miRNA-93, miRNA-216a, and miRNA-21 may be implicated in the pathogenesis of DN, while miRNA-25 may have a reno-protective role. More studies are needed to document the value of these miRNAs as diagnostic biomarkers as well as therapeutic targets in DN.